Wednesday, April 24, 2019 7:08:13 PM
But since you brought up numbers:
Instead of putting that same 10k in a stock (any stock) with the hope it'll go to the moon "in a few years",
Competently daytrade it over a year.
2019 has 252 trading days. Averaged out earning of $500/day is $126 000 of earnings in one year + your original 10k. If we average it out to two years, that's over a Quarter Million.
Far more likely than the "buy and hope for a few years" strategy. But that's Me.
GLTA.
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 09:00:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:00:40 PM
- Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial • PR Newswire (US) • 06/14/2024 12:00:00 PM
- Moleculin to Present at the Virtual Investor Pitch Conference • PR Newswire (US) • 06/12/2024 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/07/2024 09:05:48 PM
- Moleculin to Participate in the Virtual Investor Lunch Break Series • PR Newswire (US) • 06/05/2024 12:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:32:14 PM
- Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress • PR Newswire (US) • 05/16/2024 12:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:38:16 PM
- Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) • PR Newswire (US) • 05/15/2024 12:38:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:16:53 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/13/2024 02:53:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:30:14 AM
- Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/13/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:30:13 PM
- Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin • PR Newswire (US) • 05/09/2024 12:30:00 PM
- Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 05/08/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:55:19 PM
- Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data • PR Newswire (US) • 05/07/2024 12:55:00 PM
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 • PR Newswire (US) • 05/02/2024 01:00:00 PM
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin • PR Newswire (US) • 05/01/2024 12:50:00 PM
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) • PR Newswire (US) • 04/18/2024 12:30:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM